帕博利珠单抗免疫治疗联合仑伐替尼分子靶向治疗在晚期肝癌患者中的效果及安全性

打开文本图片集

Efficacy and Safety of Pembrolizumab Immunotherapy Combined with Lenvatinib Molecular Targeted Therapy in Patients with Advanced Liver Cancer/ZHANG Jianping， BIAN Weigang， CHEN Surong，CHEN Yan.//Medical Innovation ofChina，2025，22（19）： 045-048

[Abstract] Objective： To investigate the clinical effect and safety of Pembrolizumab immunotherapy combined with Lenvatinib molecular targeted therapy inpatients with advanced liver cancer.Method：Atotalof 100 patients with advanced liver cancer in the Department of Oncology， Yancheng NO.1 People's Hospital from January 2021 to January 2O24 were selected as the research subjects.According to the random number table method，the patients were divided into the study group （n=5O） and the control group （ n =50）.The control group was treated with Pembrolizumab，and the study group was treated with Pembrolizumab and Lenvatinib.The therapeutic effect and adversereactions of the two groups were compared，and the levels of tumor indicators [vascular endothelial growth factor （VEGF），hypoxia-inducible factor-1α （HIF- ∇⋅l∝ ）and proline hydroxylase 2 （PHD2）] in both groups were monitored before and after treatment.Result： The objective response rate and disease control rate of the study group were higher than those of the control group （ P <0.05）.There were no statistically significant differences in the incidence of adverse reactions between the study group and the control group （ P >0.05）.ThelevelsofVEGF，HIF- （20号 and PHD2 in the study group after treatment were lower than those in the control group （ P <0.05）. Conclusion： The application of Pembrolizumab immunotherapy combined with Lenvatinib molecular targeted therapy in patients with advancedliver cancercan effctively improvethe tumorcontrol effct，reduce thelevelsof tumor indicators，and the adverse reactions are controllable.

[Keywords] Advanced livercancer Pembrolizumab Lenvatinib

First-author's address： Department of Oncology， Yancheng NO.1 People's Hospital， Yancheng 224600， China

doi：10.3969/j.issn.1674-4985.2025.19.011

2020年中国范围内原发性肝癌的发病率与死亡率分别排恶性肿瘤的第5位和第2位[-2]。（剩余5975字）